We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+42.02%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$301M
AUM Growth
+$81.5M
Cap. Flow
+$21.5M
Cap. Flow %
7.15%
Top 10 Hldgs %
57.04%
Holding
59
New
3
Increased
11
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$11M
2
EXEL icon
Exelixis
EXEL
+$8.09M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.53M
4
GILD icon
Gilead Sciences
GILD
+$5.06M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$4.17M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$6.4M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.52M
3
AMGN icon
Amgen
AMGN
+$3.19M
4
LLY icon
Eli Lilly
LLY
+$2.77M
5
INCY icon
Incyte
INCY
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$24M 7.98%
434,000
+40,000
+10% +$1.71M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$12.6B
$22.7M 7.54%
185,584
+15,800
+9% +$1.57M
GILD icon
3
Gilead Sciences
GILD
$185B
$22.6M 7.52%
303,284
+66,000
+28% +$5.06M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$139B
$18.5M 6.14%
64,822
-13,000
-17% -$3.52M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$15.3M 5.1%
448,000
+376,000
+522% +$11M
PTCT icon
6
PTC Therapeutics
PTCT
$5.98B
$15.1M 5.03%
299,000
+30,000
+11% +$1.47M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.13B
$14.7M 4.89%
305,000
-32,000
-9% -$1.54M
BIIB icon
8
Biogen
BIIB
$32.7B
$13.3M 4.43%
51,200
+5,500
+12% +$1.65M
NBIX icon
9
Neurocrine Biosciences
NBIX
$15.9B
$13.3M 4.41%
105,800
-1,500
-1% -$166K
AMGN icon
10
Amgen
AMGN
$236B
$12M 4%
52,000
-14,000
-21% -$3.19M
CCXI
11
DELISTED
ChemoCentryx, Inc.
CCXI
$10.5M 3.48%
191,600
+1,600
+0.8% +$87.1K
EXEL icon
12
Exelixis
EXEL
$13.7B
$10.3M 3.42%
452,534
+349,000
+337% +$8.09M
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$9.81M 3.26%
88,241
+14,600
+20% +$1.55M
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$9.12M 3.03%
55,500
-1,400
-2% -$209K
INCY icon
15
Incyte
INCY
$25.9B
$7.99M 2.66%
78,000
-21,500
-22% -$2.07M
HALO icon
16
Halozyme
HALO
$12.1B
$7.94M 2.64%
307,633
– –
REGN icon
17
Regeneron Pharmaceuticals
REGN
$83.1B
$7.02M 2.33%
+11,500
New +$6.53M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.37M 2.12%
65,859
+50,000
+315% +$4.17M
ZGNX
19
DELISTED
Zogenix, Inc.
ZGNX
$6.17M 2.05%
236,832
-44,965
-16% -$1.24M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$31.6B
$5.37M 1.79%
36,300
+14,000
+63% +$1.89M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.03M 1.67%
43,900
– –
SRPT icon
22
Sarepta Therapeutics
SRPT
$2.28B
$3.5M 1.16%
21,500
-6,600
-23% -$898K
BHVN
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.12M 1.04%
+45,000
New +$2.39M
IONS icon
24
Ionis Pharmaceuticals
IONS
$10.4B
$2.36M 0.79%
39,781
-14,000
-26% -$779K
ENTA icon
25
Enanta Pharmaceuticals
ENTA
$401M
$2.28M 0.76%
46,500
– –
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2020 Portfolio in Review

As of Q2 2020, International Biotechnology Trust held 59 positions worth $301M, up 37% from $219M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $21.5M of net new capital in Q2 2020, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $3.52M trimmed.

  • International Biotechnology Trust's largest Q2 2020 buy was Regeneron Pharmaceuticals: 11,500 shares worth $7.02M.
  • International Biotechnology Trust added most to Immunomedics Inc in Q2 2020, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $3.52M.
  • International Biotechnology Trust fully exited Merck in Q2 2020, selling an estimated $6.4M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $301M portfolio in Q2 2020.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q2 2020.
  • International Biotechnology Trust's portfolio value rose 37% quarter-over-quarter to $301M.

Based on International Biotechnology Trust's 13F filing for Q2 2020, filed 14 Jul 2020.